keyword
https://read.qxmd.com/read/38268164/rare-cause-of-hematochezia-in-children-solitary-rectal-ulcer-single-center-experience
#21
JOURNAL ARTICLE
Fatma İlknur Varol, Şükrü Güngör, Mukadder Ayşe Selimoğlu, Emine Şamdancı
BACKGROUND/AIMS: Solitary rectal ulcer syndrome (SRUS) can be overlooked, diagnosed late, or misdiagnosed, particularly in childhood. This study reviewed the 13-year experience of the authors' institution to increase clinicians' awareness of SRUS in the presence of symptoms. This paper reports the endoscopic and histopathological findings in children presenting with hematochezia. METHODS: The clinical and laboratory findings of 22 patients diagnosed with biopsy-proven SRUS in the authors' clinic between 2007 and 2020 were evaluated retrospectively...
January 25, 2024: Korean Journal of Gastroenterology, Taehan Sohwagi Hakhoe Chi
https://read.qxmd.com/read/38266937/therapeutic-effect-of-5-asa-and-hesperidin-loaded-chitosan-eudragit%C3%A2-s100-nanoparticles-as-a-ph-sensitive-carrier-for-local-targeted-drug-delivery-in-a-rat-model-of-ulcerative-colitis
#22
JOURNAL ARTICLE
Armana Abdollahy, Majid Salehi, Solmaz Mahami, Andreas Bernkop-Schnürch, Hamid Vahedi, Anneh Mohammad Gharravi, Mohsen Mehrabi
Ulcerative colitis (UC) is an idiopathic disease characterized by colonic mucosal tissue destruction secondary to an excessive immune response. We synthesized pH-sensitive cross-linked chitosan/Eudragit® S100 nanoparticles (EU S100/CS NPs) as carriers for 5-aminosalicylic acid (5-ASA) and hesperidin (HSP), then conducted in-vitro and in-vivo studies and evaluated the therapeutic effects. In-vitro analysis revealed that the 5-ASA-loaded EU S100/CS NPs and the HSP-loaded EU S100/CS NPs had smooth and curved surfaces and ranged in size between 250 and 300 nm, with a zeta potential of 32 to 34 mV...
January 22, 2024: International Journal of Pharmaceutics
https://read.qxmd.com/read/38255764/involvement-of-embryo-derived-and-monocyte-derived-intestinal-macrophages-in-the-pathogenesis-of-inflammatory-bowel-disease-and-their-prospects-as-therapeutic-targets
#23
REVIEW
Shujun Zuo, Liping Jiang, Luying Chen, Weikang Wang, Jintao Gu, Jiajie Kuai, Xuezhi Yang, Yang Ma, Chenchen Han, Wei Wei
Inflammatory bowel disease (IBD) is a group of intestinal inflammatory diseases characterized by chronic, recurrent, remitting, or progressive inflammation, which causes the disturbance of the homeostasis between immune cells, such as macrophages, epithelial cells, and microorganisms. Intestinal macrophages (IMs) are the largest population of macrophages in the body, and the abnormal function of IMs is an important cause of IBD. Most IMs come from the replenishment of blood monocytes, while a small part come from embryos and can self-renew...
January 5, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38191781/ph-and-redox-dual-response-nano-suppository-for-the-treatment-of-ulcerative-colitis
#24
JOURNAL ARTICLE
Yijun Wu, Jinfeng Song, Xiaochen Wang, Longxia Li, Jie Chang, Yunfeng Ma
To improve treatment compliance and reach sustained and controlled drug release in the colon, we developed a hollow mesoporous silica nano-suppository that responded to both pH and redox stimuli. Firstly, we prepared hollow mesoporous silica nanoparticles containing disulfide bonds (HMSN-SS) and loaded them with 5-ASA. Secondly, we modified the surface of HMSN-SS with polydopamine (PDA) and chitosan (CS) and molded the suppository, which we named 5-ASA@HMSN-SS-PDA-CS (5-ASA@HSPC). By administering 5-ASA@HSPC rectally, it acted directly on the affected area...
January 8, 2024: Drug Delivery and Translational Research
https://read.qxmd.com/read/38191328/efficacy-and-safety-of-tacrolimus-in-older-adults-with-ulcerative-colitis-a-retrospective-study
#25
JOURNAL ARTICLE
Ayumi Ito, Syun Murasugi, Teppei Omori, Shinichi Nakamura, Katsutoshi Tokushige
BACKGROUND/AIMS: The prevalence of ulcerative colitis (UC) has been increasing, also in older adults. Here, we retrospectively compared the efficacy and safety of tacrolimus (TAC) in older and younger patients with UC. METHODS: We included younger (age < 65 years; n = 116) and older patients (age ≥ 65 years; n = 21) with UC who received TAC from April 2009 through December 2022(mean follow-up, 1230 ± 175 days) and achieved remission...
January 8, 2024: BMC Gastroenterology
https://read.qxmd.com/read/38160439/clinicopathologic-characterization-of-lymphocytic-colitis-in-the-pediatric-population
#26
JOURNAL ARTICLE
Iván A González, Maire Conrad, Sarah Weinbrom, Trusha Patel, Judith R Kelsen, Pierre Russo
BACKGROUND: Lymphocytic colitis (LC) in the pediatric population has been associated with immune dysregulation. METHODS: Single-center retrospective study of pediatric LC. RESULTS: 50 patients (35 female, 70%) with a median age of 12 years at diagnosis (interquartile range: 5.7-15.8) of LC were identified. At presentation, 11 patients (22%) had malnutrition, 16 (32%) had a known underlying immune dysregulation, 4 (8%) had celiac disease (CD), and none had a diagnosis of inflammatory bowel disease...
December 31, 2023: Pediatric and Developmental Pathology
https://read.qxmd.com/read/38152693/ethyl-acetate-extract-of-terminalia-chebula-alleviates-dss-induced-ulcerative-colitis-in-c57bl-6-mice
#27
JOURNAL ARTICLE
Wan-Rong Dong, Yao-Yao Li, Tian-Tian Liu, Gao Zhou, Yu-Xin Chen
Background: The Chinese pharmacopeia records Terminalia chebula as effective in treating prolonged diarrhea and dysentery, blood in the stool, and prolapse. Modern pharmacological research proves it has multiple pharmacological benefits, including antioxidant, anti-inflammatory, analgesic, hepatoprotective, neuroprotective, and other properties. Objectives: This study aims to clarify the role of Terminalia chebula 's ethyl acetate extract (TCEA) on ulcerative colitis (UC) induced by dextran sodium sulfate (DSS) in mice, as well as explore the potential mechanism of action...
2023: Frontiers in Pharmacology
https://read.qxmd.com/read/38138595/oxidation-of-mesalamine-under-phenoloxidase-or-peroxidase-like-enzyme-catalysis
#28
JOURNAL ARTICLE
Rimaz El Zein, Pompilia Ispas-Szabo, Maziar Jafari, Mohamed Siaj, Mircea Alexandru Mateescu
Mesalamine, also called 5-ASA (5-aminosalicylic acid), is a largely used anti-inflammatory agent and is a main choice to treat Ulcerative Colitis. This report is aimed to investigate enzymatic processes involved in the oxidation of mesalamine to better understand some of its side-effects. Oxidation with oxygen (catalyzed by ceruloplasmin) or with hydrogen peroxide (catalyzed by peroxidase or hemoglobin) showed that these oxidases, despite their different mechanisms of oxidation, could recognize mesalamine as a substrate and trigger its oxidation to a corresponding quinone-imine...
December 15, 2023: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/38110964/polystyrene-nanobeads-exacerbate-chronic-colitis-in-mice-involving-in-oxidative-stress-and-hepatic-lipid-metabolism
#29
JOURNAL ARTICLE
Juan Ma, Yin Wan, Lingmin Song, Luchen Wang, Huimei Wang, Yingzhi Li, Danfei Huang
BACKGROUND: Nanoplastics (NPs) are omnipresent in our lives as a new type of pollution with a tiny size. It can enter organisms from the environment, accumulate in the body, and be passed down the food chain. Inflammatory bowel disease (IBD) is a nonspecific intestinal inflammatory disease that is recurrent and prevalent in the population. Given that the intestinal features of colitis may affect the behavior and toxicity of NPs, it is imperative to clarify the risk and toxicity mechanisms of NPs in colitis models...
December 18, 2023: Particle and Fibre Toxicology
https://read.qxmd.com/read/38095251/-overview-and-update-on-treatment-in-ulcerative-colitis
#30
JOURNAL ARTICLE
Laura Rossier, Christoph Matter
Ulcerative colitis is characterized by a chronic intestinal inflammation limited to the mucosa of the colon, of variable proximal extent. Main symptoms are diarrhea, possibly bloody, and abdominal pain. It evolves with phases of relapse and remission. The diagnosis of ulcerative colitis is made based on clinical, endoscopic, and histologic findings. Currently, the various drug treatment options act by, among other things, reducing the activity of the immune system locally or systemically. In mild to moderate forms, 5-ASA remains the mainstay of both induction and maintenance treatment...
December 2023: Therapeutische Umschau. Revue Thérapeutique
https://read.qxmd.com/read/38059454/management-and-treatment-optimization-of-patients-with-mild-to-moderate-ulcerative-colitis
#31
REVIEW
Ferdinando D'Amico, Ernesto Fasulo, Vipul Jairath, Kristine Paridaens, Laurent Peyrin-Biroulet, Silvio Danese
INTRODUCTION: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a significant health-care burden worldwide. While medical therapy aims to induce and maintain remission, optimal management of mild to moderate UC remains challenging due to heterogeneity in severity classifications and non-standardized approaches. This comprehensive review summarizes current evidence and knowledge gaps to optimize clinical decision-making in patients with mild to moderate UC. AREAS COVERED: After an extensive literature search of PubMed, Medline, and Embase through August 2023, we provide an overview of definitions utilized to characterize mild to moderate UC severity and established therapeutic targets...
December 7, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/38034435/natural-history-of-pediatric-patients-with-crohn-s-disease-treated-with-mesalamine-therapy
#32
JOURNAL ARTICLE
Denise D Young, Sharon Perry, Sindhoosha Malay, Thomas J Sferra, Michael Finkler, Jonathan Moses
BACKGROUND: 5-aminosalicylates (5-ASA) are used to treat mild to moderate ulcerative colitis. Despite their lack of efficacy in Crohn disease (CD), they are still used in real-world practice. Additionally, when patients have progressive disease, they may escalate to biologic therapy, at which time 5-ASA may or may not be discontinued. OBJECTIVES: The aim of this study is to assess the clinical outcomes of patients started on 5-ASA for the treatment of pediatric CD...
November 2023: JPGN reports
https://read.qxmd.com/read/38023976/concomitant-5-aminosalicylic-acid-treatment-does-not-affect-6-thioguanine-nucleotide-levels-in-patients-with-inflammatory-bowel-disease-on-thiopurines
#33
JOURNAL ARTICLE
Rahel Looser, Michael Doulberis, Jean-Benoit Rossel, Yannick Franc, Daniel Müller, Luc Biedermann, Gerhard Rogler
BACKGROUND: There are conflicting data as to whether co-treatment with 5-aminosalicylic acid (5-ASA) in patients with inflammatory bowel disease (IBD) under azathioprine (AZA) or 6-mercaptopurine (6-MP) therapy may influence 6-thioguanine nucleotide (6-TGN) concentrations, and whether this combination puts patients at risk of side-effects. The aim of the study was to determine 6-TGN levels in patients treated with AZA/6-MP, either alone or in combination with 5-ASA. METHODS: Available blood samples from patients treated with AZA or 6-MP were retrieved from the Swiss IBD Cohort Study (SIBDCS)...
2023: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://read.qxmd.com/read/38017539/solubility-of-mesalazine-in-pseudo-binary-mixtures-of-choline-chloride-ethylene-glycol-deep-eutectic-solvent-and-water-at-293-15-k-to-313-15-k
#34
JOURNAL ARTICLE
Elina Armani, Parisa Jafari, Salar Hemmati, Elaheh Rahimpour, Mohammad Barzegar-Jalali, Abolghasem Jouyban
Mesalazine (5-ASA) is a medication utilized to treat inflammatory bowel diseases involving ulcerative colitis and Crohn's disease. Mesalazine has fewer side effects but the low solubility and bioavailability of it is responsible for its delayed onset of action. Hence, the goal of this study is to determine the molar solubility of 5-ASA in aqueous pseudo-binary mixtures containing low toxic biocompatible choline chloride/ethylene glycol deep eutectic solvent (ChCl/EG DES) with DES mass fraction of 0.0-1...
November 28, 2023: BMC chemistry
https://read.qxmd.com/read/38010363/modulating-gut-microbiota-prevents-anastomotic-leak-to-reduce-local-implantation-and-dissemination-of-colorectal-cancer-cells-after-surgery
#35
JOURNAL ARTICLE
Roy Hajjar, Manon Oliero, Gabriela Fragoso, Ayodeji Samuel Ajayi, Ahmed Amine Alaoui, Hervé Vennin Rendos, Annie Calvé, Thibault Cuisiniere, Claire Gerkins, Sophie Thérien, Nassima Taleb, François Dagbert, Herawaty Sebajang, Rasmy Loungnarath, Frank Schwenter, Richard Ratelle, Ramses Wassef, Eric De Broux, Carole Richard, Manuela M Santos
PURPOSE: Anastomotic leak (AL) is a major complication in colorectal cancer surgery and consists of the leakage of intestinal content through a poorly healed colonic wound. Colorectal cancer recurrence after surgery is a major determinant of survival. We hypothesize that AL may allow cancer cells to escape the gut and lead to cancer recurrence and that improving anastomotic healing may prevent local implantation and metastatic dissemination of cancer cells. EXPERIMENTAL DESIGN: We investigated the association between AL and postoperative outcomes in patients with colorectal cancer...
February 1, 2024: Clinical Cancer Research
https://read.qxmd.com/read/37976806/discovery-of-a-novel-gpr35-agonist-with-high-and-equipotent-species-potency-for-oral-treatment-of-ibd
#36
JOURNAL ARTICLE
Zhaoxiang Song, Dan Lu, Jun Sun, Yangliang Ye, Jiahui Fang, Kai Wang, Shimeng Guo, Qing Zhang, Xinheng He, Xin Xie, Jianhua Shen
The G protein-coupled receptor 35 (GPR35) has been identified as a potential target in the treatment of inflammatory bowel disease (IBD). However, the lack of high and equipotent agonists on both human and mouse GPR35 has limited the in vivo study of GPR35 agonists in mouse models of IBD. In this study, structural modifications to lodoxamide provides a series of high and equivalent agonists on human, mouse, and rat GPR35. These molecules eliminate the species selectivity of human to mouse and rat orthologs that have been prevalent with GPR35 agonists including lodoxamide...
November 1, 2023: Bioorganic & Medicinal Chemistry
https://read.qxmd.com/read/37959394/treatment-of-patients-with-mild-to-moderate-ulcerative-colitis-a-middle-east-expert-consensus
#37
REVIEW
Sameer Al Awadhi, Mohamed Alboraie, Emad Aldin Albaba, Abdulelah Almutairdi, Monther Alsaad, Nahla Azzam, Husam Barakat, Ferdinando D'Amico, Silvio Danese, Mohamed El Kady, Hossam Ghoneim, Waseem Hamoudi, Ahmad Jazzar, Mahmoud Mosli, Hany Shehab, Awni Abu Sneineh
The prevalence of ulcerative colitis (UC) in the Middle East is increasing, impacting the economic and healthcare burden. The management of patients with mild to moderate UC is still a challenge as several factors can affect optimal care, including drug choice, induction and maintenance dose, treatment optimization and de-escalation, therapy duration, monitoring, and safety profile. We conducted an expert consensus to standardize the management of patients with mild to moderate UC. Sixteen experts in inflammatory bowel diseases, through a well-established and accepted Delphi methodology, voted and approved eight statements in order to provide practical guidance to clinicians in the Middle East...
November 4, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/37952559/optimization-cellular-uptake-and-in-vivo-evaluation-of-eudragit-s100-coated-bile-salt-containing-liposomes-for-oral-colonic-delivery-of-5-aminosalicylic-acid
#38
JOURNAL ARTICLE
Hamid Alghurabi, Huda Jassim Muhammad, Tatsuaki Tagami, Koki Ogawa, Tetsuya Ozeki
Eudragit S100-coated bile salt-containing liposomes were prepared and optimized by experimenting with different variables, including bile salt type and concentration, and the method of incorporation into liposomes using a model hydrophilic compound, 5-aminosalicylic acid (5-ASA). After optimizing the formulation, cellular uptake, and animal pharmacokinetic experiments were performed. The inclusion of sodium glycocholate (SG) into liposomes decreased liposome particle size and entrapment efficiency significantly but had no effect on zeta potential...
November 10, 2023: International Journal of Pharmaceutics
https://read.qxmd.com/read/37952112/anti-tumor-necrosis-factor-alpha-versus-corticosteroids-a-threefold-difference-in-the-occurence-of-venous-thromboembolism-in-inflammatory-bowel-disease-a-systematic-review-and-meta-analysis
#39
JOURNAL ARTICLE
Hajnal Székely, Laura Mária Tó Th, Anett Rancz, Anna Walter, Nelli Farkas, Miklós Domonkos Sárközi, Szilárd Váncsa, Bálint Erőss, Péter Hegyi, Pál Miheller
BACKGROUND, AIMS: Patients with inflammatory bowel disease (IBD) have a more than twofold higher risk of venous thromboembolic events (VTE) than the general population. The etiology is complex, and the role of medication is not precisely defined.We aimed to assess the effect of anti-tumor necrosis factor alpha (anti-TNFα) drugs and conventional anti-inflammatory therapy, namely corticosteroids (CS), immunomodulators (IM), and 5-aminosalicylates (5-ASA) on VTE in IBD. METHODS: A systematic search was performed in five databases on the 22nd of November 2022...
November 11, 2023: Journal of Crohn's & Colitis
https://read.qxmd.com/read/37950138/water-soluble-se-containing-proteins-from-chicken-alleviate-dss-induced-ulcerative-colitis-in-mice-via-inhibiting-tlr4-myd88-pathway-and-protecting-the-goblet-cell-pathway
#40
JOURNAL ARTICLE
Yuancheng Li, Yanlong Xu, Xin Hu, Chenxi Li, Lulu Wei, Xinlei Wang, Yi Jin, Zhongqiu Hu
The influence of water-soluble selenium-containing proteins (WSSeP) in chicken on ulcerative colitis (UC) is not known. This work aims to investigate the effect of two WSSeP including h-Se with 1.78 μg Se/g and l-Se with 1.04 μg Se/g on mice UC induced by dextran sodium sulfate (DSS) versus 5-aminosalicylic acid (5-ASA). Seventy C57BL/6 mice were randomly divided into seven groups: groups 1 and 7 were given normal saline. Group 2 to group 4 were administrated orally 500, 1500, and 3000 mg/kg/day h-Se, respectively...
November 11, 2023: Biological Trace Element Research
keyword
keyword
35709
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.